Lonely killers

References

• Campoli M, Ferris R, Ferrone S, Wang X. Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin Cancer Res 2010; 16:11 - 20; PMID: 20028761; http://dx.doi.org/10.1158/1078-0432.CCR-09-2345
   PubMed Web of Science ®Google Scholar
• Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10:301 - 316; PMID: 20414204; http://dx.doi.org/10.1038/nri2761
   PubMed Web of Science ®Google Scholar
• Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317 - 327; PMID: 20414205; http://dx.doi.org/10.1038/nri2744
   PubMed Web of Science ®Google Scholar
• Scolnik PA. mAbs: a business perspective. MAbs 2009; 1:179 - 184; PMID: 20061824; http://dx.doi.org/10.4161/mabs.1.2.7736
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 2011; 3:76 - 99; PMID: 21051951; http://dx.doi.org/10.4161/mabs.3.1.13895
   PubMed Web of Science ®Google Scholar
• Goldman B, DeFrancesco L. The cancer vaccine roller coaster. Nat Biotechnol 2009; 27:129 - 139; PMID: 19204689; http://dx.doi.org/10.1038/nbt0209-129
   PubMed Web of Science ®Google Scholar
• Carballido E, Fishman M. Sipuleucel-T: Prototype for development of anti-tumor vaccines. Curr Oncol Rep 2011; 13:112 - 119; PMID: 21243538; http://dx.doi.org/10.1007/s11912-011-0152-5
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet?. Immunol Rev 2011; 239:27 - 44; PMID: 21198663; http://dx.doi.org/10.1111/j.1600-065X.2010.00979.x
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646 - 674; PMID: 21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10:345 - 352; PMID: 20414207; http://dx.doi.org/10.1038/nri2747
   PubMed Web of Science ®Google Scholar
• Lopez-Requena A, Burrone OR. Anti-idiotypic antibodies and “tumor-only” antigens: an update. Open Immunol J 2009; 2:1 - 8; http://dx.doi.org/10.2174/1874226200902010001
   Google Scholar
• Hinojosa LE, Hernandez T, de Acosta CM, Montero E, Perez R, Lopez-Requena A. Construction of a recombinant non-mitogenic anti-human CD3 antibody. Hybridoma (Larchmt) 2010; 29:115 - 124; PMID: 20443703; http://dx.doi.org/10.1089/hyb.2009.0042
   PubMed Web of Science ®Google Scholar
• Alonso R, Huerta V, de Leon J, Piedra P, Puchades Y, Guirola O, et al. Towards the definition of a chimpanzee and human conserved CD6 domain 1 epitope recognized by T1 monoclonal antibody. Hybridoma (Larchmt) 2008; 27:291 - 301; PMID: 18707547; http://dx.doi.org/10.1089/hyb.2008.0007
   PubMed Web of Science ®Google Scholar
• Fernandez LE, Gabri MR, Guthmann MD, Gomez RE, Gold S, Fainboim L, et al. NGcGM3 ganglioside: a privileged target for cancer vaccines. Clin Dev Immunol 2010; 2010:814397; PMID: 21048926; http://dx.doi.org/10.1155/2010/814397
   PubMedGoogle Scholar
• Liu XY, Pop LM, Vitetta ES. Engineering therapeutic monoclonal antibodies. Immunol Rev 2008; 222:9 - 27; PMID: 18363992; http://dx.doi.org/10.1111/j.1600-065X.2008.00601.x
   PubMed Web of Science ®Google Scholar
• Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104:2635 - 2642; PMID: 15226177; http://dx.doi.org/10.1182/blood-2004-03-1110
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010; 47:115 - 123; PMID: 20350658; http://dx.doi.org/10.1053/j.seminhematol.2010.01.011
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009; 16:3 - 11; PMID: 18846107; http://dx.doi.org/10.1038/cdd.2008.150
   PubMed Web of Science ®Google Scholar
• Karagiannis SN, Bracher MG, Hunt J, McCloskey N, Beavil RL, Beavil AJ, et al. IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol 2007; 179:2832 - 2843; PMID: 17709497
   PubMed Web of Science ®Google Scholar
• Karagiannis SN, Bracher MG, Beavil RL, Beavil AJ, Hunt J, McCloskey N, et al. Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells. Cancer Immunol Immunother 2008; 57:247 - 263; PMID: 17657488; http://dx.doi.org/10.1007/s00262-007-0371-7
   PubMed Web of Science ®Google Scholar
• Karagiannis P, Singer J, Hunt J, Gan SK, Rudman SM, Mechtcheriakova D, et al. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol Immunother 2009; 58:915 - 930; PMID: 18941743; http://dx.doi.org/10.1007/s00262-008-0607-1
   PubMed Web of Science ®Google Scholar
• Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M, et al. Allergo Oncology: the role of IgE-mediated allergy in cancer. Allergy 2008; 63:1255 - 1266; PMID: 18671772; http://dx.doi.org/10.1111/j.1398-9995.2008.01768.x
   PubMed Web of Science ®Google Scholar
• Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004; 4:592 - 603; PMID: 15286739; http://dx.doi.org/10.1038/nrc1412
   PubMed Web of Science ®Google Scholar
• Leist M, Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001; 2:589 - 598; PMID: 11483992; http://dx.doi.org/10.1038/35085008
   PubMed Web of Science ®Google Scholar
• Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G. Cell death assays for drug discovery. Nat Rev Drug Discov 2011; 10:221 - 237; PMID: 21358741; http://dx.doi.org/10.1038/nrd3373
   PubMed Web of Science ®Google Scholar
• Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity and immunoescape. J Clin Oncol 2010; 28:4390 - 4399; PMID: 20697078; http://dx.doi.org/10.1200/JCO.2009.27.6360
   PubMed Web of Science ®Google Scholar
• Reslan L, Dalle S, Dumontet C. Understanding and circumventing resistance to anticancer monoclonal antibodies. MAbs 2009; 1:222 - 229; PMID: 20065642; http://dx.doi.org/10.4161/mabs.1.3.8292
   PubMed Web of Science ®Google Scholar
• Alpizar YA, Chain B, Collins MK, Greenwood J, Katz D, Stauss HJ, et al. Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies. Cancer Immunol Immunother 2011; 60:1127 - 1135; PMID: 21479639; http://dx.doi.org/10.1007/s00262-011-0985-7
   PubMed Web of Science ®Google Scholar
• Perez R, Moreno E, Garrido G, Crombet T. EGFR-targeting as a biological therapy: understanding Nimotuzumab's clinical effects. Cancers 2011; 3:2014 - 2031; http://dx.doi.org/10.3390/cancers3022014
   PubMedGoogle Scholar
• Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a “vaccinal effect” of rituximab. Blood 2009; 113:3809 - 3812; PMID: 19196657; http://dx.doi.org/10.1182/blood-2008-10-185280
   PubMed Web of Science ®Google Scholar
• Garrido G, Sanchez B, Rodriguez HM, Lorenzano P, Alonso D, Fernandez LE. 7A7 MAb: a new tool for the pre-clinical evaluation of EGFR-based therapies. Hybrid Hybridomics 2004; 23:168 - 175; PMID: 15312307; http://dx.doi.org/10.1089/1536859041224280
   PubMedGoogle Scholar
• Garrido G, Lorenzano P, Sanchez B, Beausoleil I, Alonso DF, Perez R, et al. T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies. Cancer Immunol Immunother 2007; 56:1701 - 1710; PMID: 17415565; http://dx.doi.org/10.1007/s00262-007-0313-4
   PubMed Web of Science ®Google Scholar
• Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature 2000; 407:784 - 788; PMID: 11048729; http://dx.doi.org/10.1038/35037722
   PubMed Web of Science ®Google Scholar
• Matzinger P. An innate sense of danger. Ann NY Acad Sci 2002; 961:341 - 342; PMID: 12081934; http://dx.doi.org/10.1111/j.1749-6632.2002.tb03118.x
   PubMed Web of Science ®Google Scholar
• Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008; 8:279 - 289; PMID: 18340345; http://dx.doi.org/10.1038/nri2215
   PubMed Web of Science ®Google Scholar
• Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009; 9:353 - 363; PMID: 19365408; http://dx.doi.org/10.1038/nri2545
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Casares N, Pequignot MO, Chaput N, Albert ML, Kroemer G. Immune response against dying tumor cells. Adv Immunol 2004; 84:131 - 179; PMID: 15246252; http://dx.doi.org/10.1016/S0065-2776(04)84004-5
   PubMed Web of Science ®Google Scholar
• Hellström I, Garrigues HJ, Garrigues U, Hellstrom KE. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res 1990; 50:2183 - 2190; PMID: 1690595
   PubMed Web of Science ®Google Scholar
• Ajani JA, Kelsen DP, Haller D, Hargraves K, Healey D. A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. Cancer J 2000; 6:78 - 81; PMID: 11069223
   PubMed Web of Science ®Google Scholar
• Saleh MN, Sugarman S, Murray J, Ostroff JB, Healey D, Jones D, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol 2000; 18:2282 - 2292; PMID: 10829049
   PubMed Web of Science ®Google Scholar
• Posey JA, Khazaeli MB, Bookman MA, Nowrouzi A, Grizzle WE, Thornton J, et al. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res 2002; 8:3092 - 3099; PMID: 12374676
   PubMed Web of Science ®Google Scholar
• Garrigues J, Garrigues U, Hellstrom I, Hellstrom KE. Ley specific antibody with potent anti-tumor activity is internalized and degraded in lysosomes. Am J Pathol 1993; 142:607 - 622; PMID: 8434651
   PubMed Web of Science ®Google Scholar
• Matsuoka S, Asano Y, Sano K, Kishimoto H, Yamashita I, Yorifuji H, et al. A novel type of cell death of lymphocytes induced by a monoclonal antibody without participation of complement. J Exp Med 1995; 181:2007 - 2015; PMID: 7759995; http://dx.doi.org/10.1084/jem.181.6.2007
   PubMed Web of Science ®Google Scholar
• Bhat NM, Bieber MM, Stevenson FK, Teng NN. Rapid cytotoxicity of human B lymphocytes induced by VH4-34 (VH4.21) gene-encoded monoclonal antibodies. Clin Exp Immunol 1996; 105:183 - 190; PMID: 8697629; http://dx.doi.org/10.1046/j.1365-2249.1996.d01-733.x
   PubMed Web of Science ®Google Scholar
• Bhat NM, Bieber MM, Hsu FJ, Chapman CJ, Spellerberg M, Stevenson FK, et al. Rapid cytotoxicity of human B lymphocytes induced by VH4-34 (VH4.21) gene-encoded monoclonal antibodies, II. Clin Exp Immunol 1997; 108:151 - 159; PMID: 9097924; http://dx.doi.org/10.1046/j.1365-2249.1997.d01-976.x
   PubMed Web of Science ®Google Scholar
• Zhang C, Xu Y, Gu J, Schlossman SF. A cell surface receptor defined by a mAb mediates a unique type of cell death similar to oncosis. Proc Natl Acad Sci USA 1998; 95:6290 - 6295; PMID: 9600958; http://dx.doi.org/10.1073/pnas.95.11.6290
   PubMed Web of Science ®Google Scholar
• Ma F, Zhang C, Prasad KV, Freeman GJ, Schlossman SF. Molecular cloning of Porimin, a novel cell surface receptor mediating oncotic cell death. Proc Natl Acad Sci USA 2001; 98:9778 - 9783; PMID: 11481458; http://dx.doi.org/10.1073/pnas.171322898
   PubMed Web of Science ®Google Scholar
• Loo D, Pryer N, Young P, Liang T, Coberly S, King KL, et al. The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo. Mol Cancer Ther 2007; 6:856 - 865; PMID: 17363480; http://dx.doi.org/10.1158/1535-7163.MCT-06-0581
   PubMed Web of Science ®Google Scholar
• Coberly SK, Chen FZ, Armanini MP, Chen Y, Young PF, Mather JP, et al. The RAV12 monoclonal antibody recognizes the N-linked glycotope RAAG12: expression in human normal and tumor tissues. Arch Pathol Lab Med 2009; 133:1403 - 1412; PMID: 19722746
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Rosen LS, Rocha-Lima CM, Marshall J, Jones S, Cohen RB, et al. Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma. Clin Cancer Res 2010; 16:1673 - 1681; PMID: 20179219; http://dx.doi.org/10.1158/1078-0432.CCR-09-2263
   PubMed Web of Science ®Google Scholar
• Choo AB, Tan HL, Ang SN, Fong WJ, Chin A, Lo J, et al. Selection against undifferentiated human embryonic stem cells by a cytotoxic antibody recognizing podocalyxin-like protein-1. Stem Cells 2008; 26:1454 - 1463; PMID: 18356574; http://dx.doi.org/10.1634/stemcells.2007-0576
   PubMed Web of Science ®Google Scholar
• Tan HL, Fong WJ, Lee EH, Yap M, Choo A. mAb 84, a cytotoxic antibody that kills undifferentiated human embryonic stem cells via oncosis. Stem Cells 2009; 27:1792 - 1801; PMID: 19544435; http://dx.doi.org/10.1002/stem.109
   PubMed Web of Science ®Google Scholar
• Carr A, Mullet A, Mazorra Z, Vazquez AM, Alfonso M, Mesa C, et al. A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 2000; 19:241 - 247; PMID: 10952412; http://dx.doi.org/10.1089/02724570050109639
   PubMed Web of Science ®Google Scholar
• Varki A. Colloquium paper: uniquely human evolution of sialic acid genetics and biology. Proc Natl Acad Sci USA 2010; 107:8939 - 8946; PMID: 20445087; http://dx.doi.org/10.1073/pnas.0914634107
   PubMed Web of Science ®Google Scholar
• Oliva JP, Valdes Z, Casaco A, Pimentel G, Gonzalez J, Alvarez I, et al. Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc. Breast Cancer Res Treat 2006; 96:115 - 121; PMID: 16322892; http://dx.doi.org/10.1007/s10549-005-9064-0
   PubMed Web of Science ®Google Scholar
• Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O, et al. Gangliosides expressed in human breast cancer. Cancer Res 1996; 56:5165 - 5171; PMID: 8912852
   PubMed Web of Science ®Google Scholar
• Mulens V, de la Torre A, Marinello P, Rodriguez R, Cardoso J, Diaz R, et al. Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients. Hum Vaccin 2010; In press PMID: 20855939
   PubMed Web of Science ®Google Scholar
• Alfonso M, Diaz A, Hernandez AM, Perez A, Rodriguez E, Bitton R, et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol 2002; 168:2523 - 2529; PMID: 11859147
   PubMed Web of Science ®Google Scholar
• Díaz A, Alfonso M, Alonso R, Saurez G, Troche M, Catala M, et al. Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin Immunol 2003; 107:80 - 89; PMID: 12763476; http://dx.doi.org/10.1016/S1521-6616(03)00036-6
   PubMed Web of Science ®Google Scholar
• Guthmann MD, Castro MA, Cinat G, Venier C, Koliren L, Bitton RJ, et al. Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients. J Immunother 2006; 29:215 - 223; PMID: 16531822; http://dx.doi.org/10.1097/01.cji.0000188502.11348.34
   PubMed Web of Science ®Google Scholar
• Neninger E, Diaz RM, de la Torre A, Rives R, Diaz A, Saurez G, et al. Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial. Cancer Biol Ther 2007; 6:145 - 150; PMID: 17218777; http://dx.doi.org/10.4161/cbt.6.2.3574
   PubMed Web of Science ®Google Scholar
• Alfonso S, Diaz RM, de la Torre A, Santiesteban E, Aguirre F, Perez K, et al. 1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients. Cancer Biol Ther 2007; 6:1847 - 1852; PMID: 18075301; http://dx.doi.org/10.4161/cbt.6.12.5000
   PubMed Web of Science ®Google Scholar
• Hernández AM, Toledo D, Martinez D, Grinan T, Brito V, Macias A, et al. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol 2008; 181:6625 - 6634; PMID: 18941253
   PubMed Web of Science ®Google Scholar
• Krengel U, Olsson LL, Martinez C, Talavera A, Rojas G, Mier E, et al. Structure and molecular interactions of a unique antitumor antibody specific for N-glycolyl GM3. J Biol Chem 2004; 279:5597 - 5603; PMID: 14627696; http://dx.doi.org/10.1074/jbc.M311693200
   PubMed Web of Science ®Google Scholar
• Carr A, Mesa C, del Carmen Arango M, Vazquez AM, Fernandez LE. In vivo and in vitro anti-tumor effect of 14F7 monoclonal antibody. Hybrid Hybridomics 2002; 21:463 - 468; PMID: 12573110; http://dx.doi.org/10.1089/153685902321043990
   PubMedGoogle Scholar
• Roque-Navarro L, Chakrabandhu K, de Leon J, Rodriguez S, Toledo C, Carr A, et al. Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol Cancer Ther 2008; 7:2033 - 2041; PMID: 18645013; http://dx.doi.org/10.1158/1535-7163.MCT-08-0222
   PubMed Web of Science ®Google Scholar
• Mateo C, Lombardero J, Moreno E, Morales A, Bombino G, Coloma J, et al. Removal of amphipathic epitopes from genetically engineered antibodies: production of modified immunoglobulins with reduced immunogenicity. Hybridoma 2000; 19:463 - 471; PMID: 11152398; http://dx.doi.org/10.1089/027245700750053959
   PubMed Web of Science ®Google Scholar
• Fernandez-Marrero Y, Roque-Navarro L, Hernandez T, Dorvignit D, Molina-Perez M, Gonzalez A, et al. A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates. Immunobiology 2011; In press
   PubMed Web of Science ®Google Scholar
• Majno G, Joris I. Apoptosis, oncosis and necrosis. An overview of cell death. Am J Pathol 1995; 146:3 - 15; PMID: 7856735
   PubMed Web of Science ®Google Scholar
• Matsuoka S, Tsurui H, Abe M, Terashima K, Nakamura K, Hamano Y, et al. A monoclonal antibody to the alpha2 domain of murine major histocompatibility complex class I that specifically kills activated lymphocytes and blocks liver damage in the concanavalin A hepatitis model. J Exp Med 2003; 198:497 - 503; PMID: 12885869; http://dx.doi.org/10.1084/jem.20021301
   PubMed Web of Science ®Google Scholar
• Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 2002; 3:586 - 599; PMID: 12154370; http://dx.doi.org/10.1038/nrm882
   PubMed Web of Science ®Google Scholar
• Takeda T, McQuistan T, Orlando RA, Farquhar MG. Loss of glomerular foot processes is associated with uncoupling of podocalyxin from the actin cytoskeleton. J Clin Invest 2001; 108:289 - 301; PMID: 11457882
   PubMed Web of Science ®Google Scholar
• Pal SK, Pegram M. Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy. Anticancer Drugs 2005; 16:483 - 494; PMID: 15846113; http://dx.doi.org/10.1097/00001813-200506000-00003
   PubMed Web of Science ®Google Scholar
• Talavera A, Friemann R, Gomez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 2009; 69:5851 - 5859; PMID: 19584289; http://dx.doi.org/10.1158/0008-5472.CAN-08-4518
   PubMed Web of Science ®Google Scholar
• Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004; 22:1646 - 1654; PMID: 15117987; http://dx.doi.org/10.1200/JCO.2004.03.089
   PubMed Web of Science ®Google Scholar
• Ramos TC, Figueredo J, Catala M, Gonzalez S, Selva JC, Cruz TM, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther 2006; 5:375 - 379; PMID: 16575203; http://dx.doi.org/10.4161/cbt.5.4.2522
   PubMed Web of Science ®Google Scholar
• Rodríguez MO, Rivero TC, del Castillo Bahi R, Muchuli CR, Bilbao MA, Vinageras EN, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 2010; 9:343 - 349; PMID: 20448462; http://dx.doi.org/10.4161/cbt.9.5.10981
   PubMed Web of Science ®Google Scholar
• Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, et al. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther 2011; 11:373 - 382; PMID: 21150278; http://dx.doi.org/10.4161/cbt.11.4.14097
   PubMed Web of Science ®Google Scholar
• Rodríguez M, Roque-Navarro L, Lopez-Requena A, Moreno E, Mateo de Acosta C, Perez R, et al. Insights into the immunogenetic basis of two ganglioside-associated idiotypic networks. Immunobiology 2007; 212:57 - 70; PMID: 17270710; http://dx.doi.org/10.1016/j.imbio.2006.08.005
   PubMed Web of Science ®Google Scholar
• Vázquez AM, Alfonso M, Lanne B, Karlsson KA, Carr A, Barroso O, et al. Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids. Hybridoma 1995; 14:551 - 556; PMID: 8770642; http://dx.doi.org/10.1089/hyb.1995.14.551
   PubMed Web of Science ®Google Scholar
• Moreno E, Lanne B, Vazquez AM, Kawashima I, Tai T, Fernandez LE, et al. Delineation of the epitope recognized by an antibody specific for N-glycolylneuraminic acid-containing gangliosides. Glycobiology 1998; 8:695 - 705; PMID: 9621110; http://dx.doi.org/10.1093/glycob/8.7.695
   PubMed Web of Science ®Google Scholar
• López-Requena A, Mateo de Acosta C, Perez A, Valle A, Lombardero J, Sosa K, et al. Chimeric anti-N-glycolyl-ganglioside and its anti-idiotypic mAbs: immunodominance of their variable regions. Hybrid Hybridomics 2003; 22:235 - 243; PMID: 14511569; http://dx.doi.org/10.1089/153685903322328965
   PubMedGoogle Scholar
• Perez A, Lombardero J, Mateo C, Mustelier G, Alfonso M, Vazquez AM, et al. Immunogenetic analysis of variable regions encoding AB1 and gamma-type AB2 antibodies from the NeuGc-containing ganglioside family. Hybridoma 2001; 20:211 - 221; PMID: 11604106; http://dx.doi.org/10.1089/027245701753179785
   PubMed Web of Science ®Google Scholar
• Fernández-Marrero Y, Hernandez T, Roque-Navarro L, Talavera A, Moreno E, Grinan T, et al. Switching on cytotoxicity by a single mutation at the heavy chain variable region of an anti-ganglioside antibody. Mol Immunol 2011; 48:1059 - 1067; PMID: 21306777; http://dx.doi.org/10.1016/j.molimm.2011.01.008
   PubMed Web of Science ®Google Scholar
• Guth AM, Zhang X, Smith D, Detanico T, Wysocki LJ. Chromatin specificity of anti-double-stranded DNA antibodies and a role for Arg residues in the third complementarity-determining region of the heavy chain. J Immunol 2003; 171:6260 - 6266; PMID: 14634143
   PubMed Web of Science ®Google Scholar
• Giles I, Lambrianides N, Latchman D, Chen P, Chukwuocha R, Isenberg D, et al. The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin. Arthritis Res Ther 2005; 7:47 - 56; PMID: 15642142; http://dx.doi.org/10.1186/ar1449
   PubMed Web of Science ®Google Scholar
• Giles I, Lambrianides N, Pattni N, Faulkes D, Latchman D, Chen P, et al. Arginine residues are important in determining the binding of human monoclonal antiphospholipid antibodies to clinically relevant antigens. J Immunol 2006; 177:1729 - 1736; PMID: 16849482
   PubMed Web of Science ®Google Scholar
• López-Requena A, De Acosta CM, Moreno E, Gonzalez M, Puchades Y, Talavera A, et al. Gangliosides, Ab1 and Ab2 antibodies I. Towards a molecular dissection of an idiotype-anti-idiotype system. Mol Immunol 2007; 44:423 - 433; PMID: 16581129
   PubMed Web of Science ®Google Scholar
• Talavera A, Eriksson A, Okvist M, Lopez-Requena A, Fernandez-Marrero Y, Perez R, et al. Crystal structure of an anti-ganglioside antibody and modelling of the functional mimicry of its NeuGc-GM3 antigen by an anti-idiotypic antibody. Mol Immunol 2009; 46:3466 - 3475; PMID: 19748674; http://dx.doi.org/10.1016/j.molimm.2009.07.032
   PubMed Web of Science ®Google Scholar
• Vázquez AM, Perez A, Hernandez AM, Macias A, Alfonso M, Bombino G, et al. Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody. Hybridoma 1998; 17:527 - 534; PMID: 9890708; http://dx.doi.org/10.1089/hyb.1998.17.527
   PubMed Web of Science ®Google Scholar
• Hernández AM, Rodriguez N, Gonzalez JE, Reyes E, Rondon T, Grinan T, et al. Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism. J Immunol 2011; 186:3735 - 3744; PMID: 21300821; http://dx.doi.org/10.4049/jimmunol.1000609
   PubMed Web of Science ®Google Scholar
• Guo Y, Chen C, Zheng Y, Zhang J, Tao X, Liu S, et al. A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death. J Biol Chem 2005; 280:41940 - 41952; PMID: 16234248; http://dx.doi.org/10.1074/jbc.M503621200
   PubMed Web of Science ®Google Scholar
• Wu GS, Kim K, el-Deiry WS. KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death. Adv Exp Med Biol 2000; 465:143 - 151; PMID: 10810622; http://dx.doi.org/10.1007/0-306-46817-4_13
   PubMed Web of Science ®Google Scholar
• Gu Z, Yamashiro J, Kono E, Reiter RE. Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism. Cancer Res 2005; 65:9495 - 9500; PMID: 16230414; http://dx.doi.org/10.1158/0008-5472.CAN-05-2086
   PubMed Web of Science ®Google Scholar
• Mone AP, Cheney C, Banks AL, Tridandapani S, Mehter N, Guster S, et al. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 2006; 20:272 - 279; PMID: 16341049; http://dx.doi.org/10.1038/sj.leu.2404014
   PubMed Web of Science ®Google Scholar
• Garrido G, Rabasa A, Sánchez B, López MV, Blanco R, López A, et al. Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody. J Immunol 2011; In press PMID: 21984704; http://dx.doi.org/10.4049/jimmunol.1003477
   PubMed Web of Science ®Google Scholar